Carcinoid Syndrome Diarrhea Treatment Market

By Therapy (Oral Therapy, Chemo Therapy, Somatostatin Analog Therapy); By End-User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Demand Analysis & Opportunity Outlook 2027

Buy Now
Report ID: 660 | Published On: Feb 10, 2023
Request Free Sample Copy

Market Segmentation

Our-in depth analysis of the global Carcinoid Syndrome Diarrhea Treatment market includes the following segments:

By Therapy

  • Oral Therapy
  • Chemo Therapy
  • Somatostatin Analog Therapy

By End-User Industries

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

Global Carcinoid Syndrome Diarrhea Treatment Market is further classified on the basis of region as follows:

  • North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Carcinoid Syndrome Diarrhea Treatment Market share

carcinoid syndrome diarrhea treatment
Get more information on this report: Request Sample PDF

Market Size & Forecast

Carcinoid Syndrome Diarrhea Treatment Market is anticipated to record a significant CAGR over the forecast period i.e. 2018-2027. On March 1, 2017 FDA approved Lexicon Pharmaceuticals, Inc. of orally administered therapy drug Xermelo for the treatment of carcinoid syndrome diarrhea. Since the treatment offered for carcinoid syndrome diarrhea are limited, multiple companies are focusing on increased research and development for new targeted delivery of disease thus targeting huge market share in carcinoid syndrome diarrhea treatment market.Carcinoid syndrome diarrhea is described by indications such as abdominal discomfort, fatigue, facial flushing, and might direct to damage in the heart valve. If carcinoid syndrome diarrhea goes untreated it may lead to excessive electrolyte imbalance, weight loss, dehydration, and other life-threatening symptoms. Thus, the growing awareness regarding these symptoms amongst the population is expected to increase the carcinoid syndrome diarrhea treatment market across the globe.On the basis of regional platform, global carcinoid syndrome diarrhea treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

carcinoid syndrome diarrhea treatment

North America is predicted to be the most dominant region in terms of revenue generation for the carcinoid syndrome diarrhea treatment market. Regulatory approval and better reimbursement policies are expected to be factor driving the growth. The high prevalence of carcinoid syndrome diarrhea in the U.S is estimated to drive the market in this region. The market in Europe is as well anticipated to grow significantly owing to the regulatory body facilitation in the development and authorization of orphan drugs.Asia Pacific especially is expected to be a lucrative market and show significant growth over the forecast period as cases of carcinoid syndrome diarrhea are increasing in this region as well as due to increase in research and development activities, and ongoing development of healthcare infrastructure in this region. 


Growth Drivers & Challenges

Carcinoid syndrome diarrhea is a rare condition. Treatment available for this condition is expected to get orphan drug status. Regulatory bodies and governments support for development of orphan drugs and incentives that are estimated to propel the carcinoid syndrome treatment market. Government allows companies to set high price for the orphan drug which in turn will generate high revenue. Carcinoid syndrome diarrhea treatment market would grow during the forecast years as many multi-national companies are focusing towards new product innovations in carcinoid syndrome diarrhea treatment. Furthermore, due to the limited available treatment process for this disease, the carcinoid syndrome diarrhea treatment market would experience a lift, and the company's manufacturing drugs would target an extensive market hence gaining huge market share in the carcinoid syndrome diarrhea treatment. Other aspects influencing the carcinoid syndrome diarrhea treatment market are increasing incidences of hormonal disorders and growing smoking habits.However, the carcinoid syndrome diarrhea treatment market may be restrained over the forecast period due to lower adoption of carcinoid syndrome diarrhea treatment in developing nations and the low availability of therapeutic options for treatment of this disease.

Carcinoid Syndrome Diarrhea Treatment Market share
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating The Market

    • Lexicon Pharmaceuticals, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis International AG (Sandoz)
    • Pharmascience Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Omega Laboratories Ltd.
    • Ipsen Biopharmaceuticals, Inc.
    • Mylan N.V.
    • Sirtex Medical Limited
    • BTG International Ltd.
    • Wockhardt Ltd.

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample